The short answer: Stage 3 cervical cancer (bachedani ke muh ka cancer, बच्चेदानी के मुँह का कैंसर) can often still be treated with the aim of cure. Many families ask “kya stage 3 cervical cancer theek ho sakta hai?”; for many women the answer is yes, although the chance is lower than at earlier stages and depends on the details. Stage 3 means the cancer has spread from the cervix to the lower part of the vagina, the pelvic side wall or the lymph nodes, but not to distant organs. The usual main treatment is chemoradiation: radiotherapy (sikai) with weekly chemotherapy, followed by internal radiotherapy (brachytherapy). An operation is usually not the main treatment at this stage. Your team will explain what your own scans and reports mean, including the exact sub-stage, the lymph nodes, your kidney function and your general health.
If you have Stage 3 or another locally advanced cervical cancer, the usual curative treatment is external-beam radiation given with weekly chemotherapy, followed by brachytherapy. This is called concurrent chemoradiation. Some patients may now be offered an additional short course of chemotherapy before chemoradiation begins. This is called induction chemotherapy or the INTERLACE approach. It can improve outcomes for selected patients, but it adds treatment and side effects and must not delay the radiation plan.
On This Page
Should Chemotherapy Be Given Before Chemoradiation?
It is now an important option to discuss for selected patients with locally advanced cervical cancer. In the phase 3 INTERLACE trial, six weekly treatments of carboplatin and paclitaxel followed promptly by standard cisplatin-based chemoradiation and brachytherapy improved five-year progression-free and overall survival compared with chemoradiation alone.
This does not mean that any chemotherapy given before radiation is beneficial. The drug combination, weekly schedule, short six-week duration and rapid transition to chemoradiation were important. Earlier studies using other drugs or longer induction courses produced mixed results. Your team should consider the exact stage, lymph nodes, kidney function, blood counts, performance status, infection or bleeding, neuropathy and whether radiation can begin without avoidable delay.
What Does Stage 3 Cervical Cancer Mean?
Stage 3 cervical cancer remains within the pelvis or has reached regional lymph nodes, but the exact substage matters:
- Stage IIIA: the cancer involves the lower third of the vagina but not the pelvic wall.
- Stage IIIB: the cancer reaches the pelvic wall or causes kidney swelling or reduced kidney function by blocking a ureter.
- Stage IIIC1: pelvic lymph nodes contain cancer.
- Stage IIIC2: para-aortic lymph nodes contain cancer.
MRI helps define the pelvic tumour. PET-CT or CT helps assess lymph nodes and distant spread. Kidney function, haemoglobin and general health can affect how treatment is delivered. Stage 3 is commonly treated with curative intent, but a complete plan needs the substage and imaging—not the stage number alone. For an overview of how cervical cancer is confirmed, staged and treated, see our guide to cervical cancer diagnosis and care.
What Is the Standard Treatment for Stage 3 Cervical Cancer?
The established curative pathway combines three parts:
- External-beam radiation therapy (EBRT): radiation is directed to the cervix, nearby tissues and the relevant lymph-node areas. It is usually given as an outpatient on weekdays, about 25 sessions over about 5 weeks.
- Concurrent chemotherapy: cisplatin is usually given weekly during EBRT. Its main role is to make cancer cells more sensitive to radiation.
- Brachytherapy: internal radiation places the radiation source close to the cervical tumour and delivers the dose needed for cure while limiting exposure to surrounding organs.
Brachytherapy is an essential component of definitive treatment for most locally advanced cervical cancers. Induction chemotherapy does not replace it. Treatment should be planned so EBRT and brachytherapy are completed within the recommended overall treatment time whenever medically possible. Our page on radiation therapy in cervical cancer care explains what to expect during external radiotherapy and brachytherapy.
What Is Induction Chemotherapy?
Induction chemotherapy is systemic chemotherapy given before chemoradiation starts. Patients often call it “chemo first.” The aim is to treat cancer cells throughout the body early and reduce the chance of distant relapse, while the planned radiation and brachytherapy control the tumour in the pelvis.
In INTERLACE, induction treatment consisted of weekly carboplatin and paclitaxel for six weeks. Patients then moved promptly to standard chemoradiation using weekly cisplatin with external-beam radiation, followed by brachytherapy. Induction chemotherapy before chemoradiation is different from:
- weekly cisplatin given during radiation;
- chemotherapy given to shrink a tumour before surgery;
- chemotherapy used for metastatic or recurrent disease; and
- immunotherapy, which follows different eligibility and treatment rules.
What Did the INTERLACE Trial Find?
INTERLACE enrolled 500 adults with locally advanced cervical cancer at 32 centres in Brazil, India, Italy, Mexico and the United Kingdom. The eligible group included FIGO 2008 stage IB1 with positive nodes and stages IB2, IIA, IIB, IIIB and IVA. Half received standard chemoradiation alone; half received six weeks of weekly carboplatin and paclitaxel first.
| Five-year outcome | Induction chemotherapy then chemoradiation | Chemoradiation alone |
|---|---|---|
| Progression-free survival | 72% | 64% |
| Overall survival | 80% | 72% |
| Grade 3 or higher adverse events | 59% | 48% |
Most patients in the induction group received at least five of the six planned weekly cycles. The median gap between induction chemotherapy and chemoradiation was seven days. Radiation quality remained central: 92% of participants received both EBRT and brachytherapy, with a median overall radiation treatment time of 45 days.
A 2025 systematic review and meta-analysis found that results across earlier studies were mixed. Benefit was more consistent when induction used a platinum–paclitaxel combination and lasted six weeks or less. Longer regimens and different combinations should not be treated as equivalent to INTERLACE.
Who May Be Considered for Induction Chemotherapy?
A multidisciplinary team may discuss the INTERLACE approach when:
- the cancer is locally advanced and definitive chemoradiation with brachytherapy is planned;
- there is no distant metastatic disease requiring another systemic-treatment strategy;
- the patient is fit enough for additional carboplatin and paclitaxel;
- blood counts, kidney and liver function allow treatment;
- neuropathy and other conditions do not make paclitaxel unsuitable; and
- the radiation team can begin chemoradiation promptly after the induction course.
The trial included a broad locally advanced group, but most participants had Stage IIB disease. A Stage 3 patient should therefore ask how closely her stage, tumour, nodes and health match the trial population.
When Might Induction Chemotherapy Not Be Suitable?
The team may prefer to start chemoradiation directly if:
- induction would cause an avoidable delay in starting radiation;
- blood counts, frailty, active infection or another illness makes extra chemotherapy unsafe;
- there is significant pre-existing numbness or nerve damage;
- kidney or liver problems affect drug choice;
- urgent control of pelvic symptoms requires a different sequence;
- the cancer has distant spread and needs a metastatic-disease plan; or
- the proposed drugs or duration do not match the evidence-supported short-course approach.
Standard chemoradiation with brachytherapy remains an evidence-based curative treatment. A patient who is not offered induction chemotherapy should ask why, but should not assume she is receiving inadequate care.
What Does the Treatment Timeline Look Like?
| Phase | Typical INTERLACE-style plan | Purpose |
|---|---|---|
| Before treatment | Imaging, examination, pathology review, blood tests, kidney assessment and radiation planning | Confirm stage, suitability and treatment fields |
| Induction phase | Weekly carboplatin plus paclitaxel for 6 weeks | Early systemic treatment |
| Transition | Prompt move to chemoradiation, commonly within about 1–2 weeks when medically possible | Avoid losing time before definitive pelvic treatment |
| Concurrent phase | EBRT with weekly cisplatin, generally over about 5 weeks | Definitive pelvic and nodal treatment |
| Brachytherapy | Planned during or immediately after EBRT according to the radiation programme | Deliver the tumour dose required for cure |
Your dates may differ because radiation planning, blood recovery, kidney function and brachytherapy technique are individual. Ask for the entire sequence in writing before induction starts, including the planned radiation start and brachytherapy dates.
Side Effects and Practical Preparation
During carboplatin and paclitaxel induction
Possible effects include tiredness, nausea, reduced blood counts, infection risk, hair loss, muscle or joint aches, numbness or tingling, and infusion reactions. Report fever, breathing difficulty, severe vomiting, new weakness or worsening numbness promptly.
During concurrent chemoradiation
Possible effects include fatigue, diarrhoea, bladder irritation, nausea, skin soreness, vaginal irritation and reduced blood counts. Weekly cisplatin can affect kidney function, hearing and electrolytes, so blood tests and hydration are important.
During brachytherapy
Brachytherapy may require anaesthesia or sedation and temporary applicators placed through the vagina. Ask how many insertions are planned, whether admission is needed, and how pain and anxiety will be managed.
Before treatment, discuss nutrition, anaemia, medicines, diabetes, kidney blockage, fertility, ovarian function, menopause, sexual health, transport and family support. Do not start supplements or herbal medicines without checking for interactions.
How Is Response Checked After Treatment?
The cervix can remain inflamed after radiation, so response is assessed at an appropriate interval rather than immediately. Follow-up usually combines symptoms, pelvic examination and imaging when indicated. A residual abnormality does not automatically mean treatment has failed; timing and specialist interpretation matter.
Routine hysterectomy is not automatically performed after definitive chemoradiation. Persistent or recurrent disease should be reviewed by a multidisciplinary gynaecological oncology team to decide whether biopsy, further imaging, salvage surgery, systemic treatment or another approach is appropriate.
Questions to Ask Your Treatment Team
- Am I being treated with curative intent?
- What is my exact stage, and are pelvic or para-aortic lymph nodes involved?
- Do I match the patients studied in INTERLACE?
- Why do you recommend induction chemotherapy or direct chemoradiation for me?
- Which induction drugs and how many weeks are planned?
- What is the confirmed date for radiation planning and treatment?
- How will you prevent induction chemotherapy from delaying chemoradiation?
- When and where will brachytherapy be performed?
- What side effects should make me call immediately?
- What support is available for anaemia, nutrition, transport, menopause and sexual health?
Frequently Asked Questions
Is induction chemotherapy the same as chemoradiation?
No. Induction chemotherapy is given first on its own. Concurrent chemoradiation gives chemotherapy at the same time as external-beam radiation.
Does “chemo first” mean radiation is no longer needed?
No. In the INTERLACE approach, induction chemotherapy is added before definitive chemoradiation. It does not replace external-beam radiation or brachytherapy.
Does every Stage 3 patient need induction chemotherapy?
No. It is an option for selected, medically fit patients when the evidence-supported schedule can be delivered without disrupting definitive radiation.
Why not give more than six weeks of chemotherapy first?
Longer induction is not proven to be better and may delay curative radiation. The strongest randomised evidence used six weekly cycles followed by a rapid transition.
Will induction chemotherapy cause more side effects?
It adds treatment. In INTERLACE, grade 3 or higher adverse events occurred in 59% with induction plus chemoradiation and 48% with chemoradiation alone.
Can induction chemotherapy shrink the tumour enough for surgery?
That is a different treatment strategy. INTERLACE used induction chemotherapy before definitive chemoradiation, not to convert patients to hysterectomy.
Is brachytherapy optional if the tumour shrinks well?
Usually no. Brachytherapy is a central part of curative radiation for locally advanced cervical cancer and should only be omitted for a specific clinical reason.
Can stage 3 cervical cancer be treated with surgery instead?
Usually not as the main treatment. At this stage, chemoradiation with brachytherapy is the standard, because an operation often cannot remove all the cancer with a clear margin and radiotherapy would usually be needed afterwards as well, adding side effects. Surgery may occasionally have a role in specific situations, decided by a multidisciplinary team.
What is the survival rate for stage 3 cervical cancer?
There is no single number. Results differ between sub-stages (3A, 3B, 3C1 and 3C2) and depend on the size of the tumour, the lymph nodes, kidney function, general health and whether the full treatment, including brachytherapy, is completed on time. Survival figures found online often mix different stages and older treatments. Ask your doctor what published figures mean for your own situation.
Related Information and Evidence
Read the main guide to cervical cancer diagnosis and treatment, the comparison of surgery versus chemoradiation in Stage 2, information about cervical cancer treatment costs, or request a treatment-plan second opinion.